AUPH

Aurinia Pharmaceuticals Inc (AUPH) | Rumor.io

Aurinia Pharmaceuticals

AUPH

Attention (50-day avg)0%

Attention rank (50-day avg)#711

Bullish sentiment (50-day avg)88%

Price to earnings ratio7.19

Market capitalization2.2B

Earnings per share2.28

Dividend yield (TTM)—

Revenue (annual)283.1M

Net income (annual)287.2M

Social

What share of all stock conversation is about AUPH?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% +0.01	0% 0	0% 0	0% -0.02

Sep 29

AUPH is set to have a patent litigation status conference on October 5th, which may be a crucial step in determining the settlement window.
The judge's interpretation of the claim language on October 5th may influence the settlement window, with a 60-day period typically following the conference before a final determination is made.
The company's CEO, Peter Greenleaf, has been ousted, and Andrew C. Talalay (Tang) has taken over, with a plan to lead the company's operational turnaround and build an autoimmune drug powerhouse.

Generated by AI

Sentiment

Of the messages about AUPH that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	98.33% +48.33	87.27% -4.25	83.72% -5.62	79.31% +8.58
Bearish	1.67% -48.33	12.73% +4.25	16.28% +5.62	20.69% -8.58

Bullish· Sep 17

The recent break-out confirmed on AUPH's chart is a strong indication of a continued upward trend, with the potential to reach $17.5+ tomorrow.
The settlement of litigations and the final nail in the short thesis will be a significant catalyst for AUPH's price, with the potential for "fireworks" when the rest of the litigations are settled.
AUPH's MACD has crossed bullish on the 5-minute chart, suggesting a strong buying signal and a potential leg higher, with the Markets and XBI looking solid and contributing to an upward trend around $18 bucks.

Bearish· Jul 2

The market is experiencing a nasty reversal of the rally, indicating a bearish signal for AUPH.
AUPH's stock price is not keeping pace with that of ARWR, suggesting that it may be undervalued compared to its peers.
The company's CEO, George Tidmarsh, may be manipulating the stock price for personal gain, as he still has many connections in the biotech industry.

Generated by AI

Topics

Of the messages about AUPH that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	0%	41.79%	48.54%
Technical Analysis	—	100%	14.93%	7.28%
Controversies	—	0%	43.28%	20.95%
Earnings	—	0%	0%	5.62%
Macro	—	0%	0%	5.99%
Analysts	—	0%	0%	11.61%

Earnings· May 12

Aurinia Pharmaceuticals ($AUPH) reported Q1 2025 earnings with an adjusted EPS of $0.16, beating estimates by $0.06.
The company's revenue increased by 24% to $62.5 million, with LUPKYNIS sales rising 25% to $60 million.
Aurinia also reported net income of $23.3 million, compared to a loss of $10.7 million in the same period of 2024, and generated $12.4 million in operating cash flow (excluding restructuring costs).

Analysts· Mar 1

Analysts at RBC Capital and HC Wainwright have lowered their price targets for Aurinia Pharmaceuticals, to $27 and $33 respectively, while maintaining an outperform rating.
The buy consensus among 14 analysts is at 86%, indicating strong confidence in Aurinia Pharmaceuticals.
A lower price target from RBC Capital could result in a 131% upside, while a lower target from HC Wainwright could result in a 179% upside.

Announcements· Mar 23

Aurinia Pharmaceuticals Inc. (AUPH) announced the appointment of Kevin Tang as Chief Executive Officer, replacing Peter Greenleaf, who will continue as a consultant to facilitate the transition.
Tang has elected to receive zero compensation from Aurinia, a significant departure from the previous regime, where CEO Greenleaf received approximately $26 million in payouts from 2019 to 2022.
The new leadership team's compensation structure, with base salaries of $300,000 for both the new CFO and COO, signals a refreshing return to fiscal discipline, with Tang, Ryan Cole, and Michael Hearne all taking modest salaries.

Controversies· Nov 3

The FDA's top drug regulator, Dr. George Tidmarsh, resigned after being sued by Aurinia Pharmaceuticals for allegedly soliciting a bribe and making false statements to damage the company's stock.
The lawsuit claims that Tidmarsh sought a bribe from Aurinia's CEO, Kevin Tang, and made false statements about the company's product, costing it around $350 million in value.
Tidmarsh's resignation comes after an investigation into his conduct, which included allegations of a "toxic" environment and a personal vendetta against Tang, a former business associate.

Technical Analysis· Jul 28

$AUPH has broken through its 52-week high with strong volume, indicating a potentially bullish trend.
The stock has formed a solid breakout from a double bottom pattern with a handle, suggesting a continuation of its upward momentum.
The 100 SMA has crossed above the 50 and 400 SMA, providing a bullish signal for $AUPH, while the 50- and 100-day simple moving averages are pinched, indicating a potential reversal.

Generated by AI

Community

Of the messages about AUPH, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	98.06%	98.22%	97.61%	92.38%
Newcomers	1.94%	1.78%	2.39%	7.62%

Regulars· Sep 29

The departure of a key executive at Aurinia Pharmaceuticals has significant implications for the company, potentially leading to a settlement window for the asset.
The upcoming patent litigation status conference on October 5th is a crucial event that will influence the judge's interpretation of the claim language, which may impact the settlement timeline.
Tang's aggressive stock purchases and leadership takeover at Aurinia Pharmaceuticals suggest a patient and long-term approach, with the goal of optimizing clinical spending and building an autoimmune drug powerhouse for the benefit of all shareholders.

Newcomers· Aug 20

Newcomers are excited about the stock's potential, with some anticipating a significant return on investment.
The settlement of patent litigation with Teva Pharmaceuticals has removed a key legal overhang and supports the commercial traction of Aurinia's Lupkynis.
The stock's recent price surge is fueled by renewed sector momentum and therapeutic developments, with the share price reaching $17.66 and marking a strong single-digit advance for the session.

Generated by AI

On August 6, Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) reported financial results for the three and six months ended June 30, and the numbers showed a company converting revenue growth into a much bigger jump in profit. Total revenue climbed 19% to $83.2 million for the quarter, but net income jumped 74% to $37.4 million, nearly four […]

14d agoYahoo Finance

Could Aurinia Pharmaceuticals (AUPH) Stock Win Big After its LUPKYNIS Patent Settlement With Teva Pharmaceuticals (TEVA)?

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) and Teva Pharmaceuticals Industries Limited (NYSE:TEVA) reached a major milestone on August 19, settling their U.S. patent dispute. Teva conceded that Aurinia’s patents covering its flagship oral lupus nephritis drug, LUPKYNIS, are valid, enforceable, and infringed by its proposed generic 7.9 mg voclosporin product. Teva agreed to delay generic commercialization until […]

1mo agoYahoo Finance

Aurinia Pharmaceuticals Chief Legal Officer Trades $355K In Company Stock

1mo agoBenzinga

Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises

AUPH settles voclosporin patent litigation with Teva, delaying potential generic competition in the United States until December 2036.

1mo agoYahoo Finance UK

Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug

1mo agoBenzinga

Also Discussed

Investors talking about AUPH also mention

#	Name	Attention
1	MYOV - Myovant Sciences Ltd.	——
2	APTO - Aptose Biosciences Inc.	——
3	TG Therapeutics Inc.TGTX	0.01%+0
4	SCYNEXIS, Inc. Common StockSCYX	0%-0.02
5	KZR - Kezar Life Sciences, Inc.	——
6	ITCI - Intra-Cellular Therapies, Inc.	——
7	GTHX - G1 Therapeutics, Inc.	——
8	Ocular Therapeutix, Inc.OCUL	0.02%-0.04
9	BioCryst Pharmaceuticals, Inc.BCRX	0.01%+0
10	Pulmatrix Inc.PULM	0%0

Aurinia Pharmaceuticals Inc

Healthcare
Biotechnology

Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on therapies for autoimmune diseases with high unmet medical need. Aurinia Pharmaceuticals develops and commercializes LUPKYNIS, an oral treatment for adults with active lupus nephritis, a serious kidney complication associated with systemic lupus erythematosus. The company also advances pipeline programs such as aritinercept, a dual inhibitor targeting B cell-activating factor and proliferation-inducing ligand for potential autoimmune indications. Aurinia Pharmaceuticals serves patients and healthcare providers in markets including the United States and Japan, with its commercial and research activities centered on immune-mediated disease treatment. Based in Edmonton, Canada, the company operates as a specialist player in the autoimmune disease segment of the biopharmaceutical industry.

Website

Location

#140, 14315 – 118 Avenue

Edmonton, AB, T5L 4S6

Canada

Social

What share of all stock conversation is about AUPH?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% +0.01	0% 0	0% 0	0% -0.02

Sep 29

AUPH is set to have a patent litigation status conference on October 5th, which may be a crucial step in determining the settlement window.
The judge's interpretation of the claim language on October 5th may influence the settlement window, with a 60-day period typically following the conference before a final determination is made.
The company's CEO, Peter Greenleaf, has been ousted, and Andrew C. Talalay (Tang) has taken over, with a plan to lead the company's operational turnaround and build an autoimmune drug powerhouse.

Generated by AI

Sentiment

Of the messages about AUPH that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	98.33% +48.33	87.27% -4.25	83.72% -5.62	79.31% +8.58
Bearish	1.67% -48.33	12.73% +4.25	16.28% +5.62	20.69% -8.58

Bullish· Sep 17

The recent break-out confirmed on AUPH's chart is a strong indication of a continued upward trend, with the potential to reach $17.5+ tomorrow.
The settlement of litigations and the final nail in the short thesis will be a significant catalyst for AUPH's price, with the potential for "fireworks" when the rest of the litigations are settled.
AUPH's MACD has crossed bullish on the 5-minute chart, suggesting a strong buying signal and a potential leg higher, with the Markets and XBI looking solid and contributing to an upward trend around $18 bucks.

Bearish· Jul 2

The market is experiencing a nasty reversal of the rally, indicating a bearish signal for AUPH.
AUPH's stock price is not keeping pace with that of ARWR, suggesting that it may be undervalued compared to its peers.
The company's CEO, George Tidmarsh, may be manipulating the stock price for personal gain, as he still has many connections in the biotech industry.

Generated by AI

Topics

Of the messages about AUPH that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	0%	41.79%	48.54%
Technical Analysis	—	100%	14.93%	7.28%
Controversies	—	0%	43.28%	20.95%
Earnings	—	0%	0%	5.62%
Macro	—	0%	0%	5.99%
Analysts	—	0%	0%	11.61%

Earnings· May 12

Aurinia Pharmaceuticals ($AUPH) reported Q1 2025 earnings with an adjusted EPS of $0.16, beating estimates by $0.06.
The company's revenue increased by 24% to $62.5 million, with LUPKYNIS sales rising 25% to $60 million.
Aurinia also reported net income of $23.3 million, compared to a loss of $10.7 million in the same period of 2024, and generated $12.4 million in operating cash flow (excluding restructuring costs).

Analysts· Mar 1

Analysts at RBC Capital and HC Wainwright have lowered their price targets for Aurinia Pharmaceuticals, to $27 and $33 respectively, while maintaining an outperform rating.
The buy consensus among 14 analysts is at 86%, indicating strong confidence in Aurinia Pharmaceuticals.
A lower price target from RBC Capital could result in a 131% upside, while a lower target from HC Wainwright could result in a 179% upside.

Announcements· Mar 23

Aurinia Pharmaceuticals Inc. (AUPH) announced the appointment of Kevin Tang as Chief Executive Officer, replacing Peter Greenleaf, who will continue as a consultant to facilitate the transition.
Tang has elected to receive zero compensation from Aurinia, a significant departure from the previous regime, where CEO Greenleaf received approximately $26 million in payouts from 2019 to 2022.
The new leadership team's compensation structure, with base salaries of $300,000 for both the new CFO and COO, signals a refreshing return to fiscal discipline, with Tang, Ryan Cole, and Michael Hearne all taking modest salaries.

Controversies· Nov 3

The FDA's top drug regulator, Dr. George Tidmarsh, resigned after being sued by Aurinia Pharmaceuticals for allegedly soliciting a bribe and making false statements to damage the company's stock.
The lawsuit claims that Tidmarsh sought a bribe from Aurinia's CEO, Kevin Tang, and made false statements about the company's product, costing it around $350 million in value.
Tidmarsh's resignation comes after an investigation into his conduct, which included allegations of a "toxic" environment and a personal vendetta against Tang, a former business associate.

Technical Analysis· Jul 28

$AUPH has broken through its 52-week high with strong volume, indicating a potentially bullish trend.
The stock has formed a solid breakout from a double bottom pattern with a handle, suggesting a continuation of its upward momentum.
The 100 SMA has crossed above the 50 and 400 SMA, providing a bullish signal for $AUPH, while the 50- and 100-day simple moving averages are pinched, indicating a potential reversal.

Generated by AI

Community

Of the messages about AUPH, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	98.06%	98.22%	97.61%	92.38%
Newcomers	1.94%	1.78%	2.39%	7.62%

Regulars· Sep 29

The departure of a key executive at Aurinia Pharmaceuticals has significant implications for the company, potentially leading to a settlement window for the asset.
The upcoming patent litigation status conference on October 5th is a crucial event that will influence the judge's interpretation of the claim language, which may impact the settlement timeline.
Tang's aggressive stock purchases and leadership takeover at Aurinia Pharmaceuticals suggest a patient and long-term approach, with the goal of optimizing clinical spending and building an autoimmune drug powerhouse for the benefit of all shareholders.

Newcomers· Aug 20

Newcomers are excited about the stock's potential, with some anticipating a significant return on investment.
The settlement of patent litigation with Teva Pharmaceuticals has removed a key legal overhang and supports the commercial traction of Aurinia's Lupkynis.
The stock's recent price surge is fueled by renewed sector momentum and therapeutic developments, with the share price reaching $17.66 and marking a strong single-digit advance for the session.

Generated by AI

Aurinia Pharmaceuticals

Social

Sep 29

Bullish· Sep 17

Bearish· Jul 2

Earnings· May 12

Analysts· Mar 1

Announcements· Mar 23

Controversies· Nov 3

Technical Analysis· Jul 28

Regulars· Sep 29

Newcomers· Aug 20

Aurinia: Lupkynis Is A Cash Cow, But Competition And Patent Risks Cap The Upside (AUPH)

Aurinia’s (AUPH) Profits Surge While Its One Drug Just Got Company

Could Aurinia Pharmaceuticals (AUPH) Stock Win Big After its LUPKYNIS Patent Settlement With Teva Pharmaceuticals (TEVA)?

Aurinia Pharmaceuticals Chief Legal Officer Trades $355K In Company Stock

Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises

Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug

Also Discussed

Aurinia Pharmaceuticals Inc

Company Information

Location

Aurinia: Lupkynis Is A Cash Cow, But Competition And Patent Risks Cap The Upside (AUPH)

Aurinia’s (AUPH) Profits Surge While Its One Drug Just Got Company

Could Aurinia Pharmaceuticals (AUPH) Stock Win Big After its LUPKYNIS Patent Settlement With Teva Pharmaceuticals (TEVA)?

Aurinia Pharmaceuticals Chief Legal Officer Trades $355K In Company Stock

Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises

Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug

Also Discussed

Social

Sep 29

Bullish· Sep 17

Bearish· Jul 2

Earnings· May 12

Analysts· Mar 1

Announcements· Mar 23

Controversies· Nov 3

Technical Analysis· Jul 28

Regulars· Sep 29

Newcomers· Aug 20